Investigational drug study for Treatment of Non-Small Cell Lung Cancer

COVID-19 update:

In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.

Trial ID:
IRB-18-7138
Michael P. Kosty, M.D.
This study will test the safety of an experimental drug called atezolizumab given in combination with other chemotherapy drugs. Patients will receive 4 cycles of chemotherapy and undergo surgical removal of their tumor. Some patients may also receive an additional 16 cycles of chemotherapy with atezolizumab.

Inclusion Criteria

  • Be 18 years of age or older
  • Have resectable Stage II, IIA, or Select IIIB Non-small cell lung cancer

Exclusion Criteria

  • Have had any prior therapy for lung cancer, including chemotherapy or radiotherapy
  • Have had any major surgical procedure within 28 days prior to starting study treatment
  • Have any significant heart disease
  • Have a history of cancer other than lung cancer within the last 5 years
  • Be pregnant or nursing

Additional Info

  • Atezolizumab is an investigational immunotherapy drug that is designed to work with the body's own immune system. It may help to activate the immune response and stop a protein called PD-L1 from preventing the body's immune system from fighting cancer.

Contact Info: